We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A Case to Support the Continued Use of Rifampin in Clinical Drug–Drug Interaction Studies.
- Authors
Bercu, Joel P.; Ponting, David J.; Ripp, Sharon L.; Dobo, Krista L.; Totah, Rheem A.; Bolleddula, Jayaprakasam
- Abstract
This article discusses the use of rifampin in clinical drug-drug interaction (DDI) studies. Rifampin is an antibiotic that is commonly used as an inducer of drug-metabolizing enzymes and transporters. However, recent reports of a nitrosamine impurity called 1-methyl-4-nitrosopiperazine (MNP) in rifampin products have raised concerns. The FDA has set a limit for MNP in rifampin products, and this has led to the search for alternative inducers for DDI studies. The authors argue that rifampin should continue to be used in these studies due to its well-established induction effects, pleiotropic effects, and safety profile compared to alternative inducers like carbamazepine and phenytoin.
- Subjects
DRUG interactions; RIFAMPIN; LEGIONNAIRES' disease; PREGNANE X receptor
- Publication
Clinical Pharmacology & Therapeutics, 2024, Vol 116, Issue 1, p34
- ISSN
0009-9236
- Publication type
Article
- DOI
10.1002/cpt.3256